ERBB2 and breast carcinoma: Fam-trastuzumab deruxtecan (Enhertu, Daiichi Sankyo) received accelerated FDA approval in December 2019 for patients with unresectable or metastatic HER2-positive breast cancer, who had previously been treated with two or more prior HER2 targeted regimens in the metastatic setting [88].